ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v18i3.2285ppharm-2021Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWПреимущества гендерно-нейтральной стратегии вакцинации для профилактики ВПЧ-ассоциированных заболеваний и искоренения ВПЧ-инфекции в целом. Актуальное состояние вакцинации против ВПЧ в миреBenefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. Current State of HPV Vaccination in the Worldhttps://orcid.org/0000-0003-4680-2925ПриваловаТ. Е.PrivalovaTatiana E.

Привалова Татьяна Евгеньевна - кандидат медицинских наук; eLibrary SPIN: 7879-4299.

119333, Москва, ул. Фотиевой, д. 10; телефон: 8 (499) 400-47-33

MD, PhD, eLibrary SPIN: 7879-4299

10 Fotievoy street, 119333, Moscow

privalova-tatyana@yandex.ruhttps://orcid.org/0000-0002-5774-6984СуровцеваО. В.SurovtsevaOlga V.

Суровцева Ольга Викторовна - ординатор кафедры факультетской педиатрии педиатрического факультета.

117997, Москва, ул. ул. Островитянова, д. 1; телефон: 8(905) 190-79-74

1 Ostrovityanova street, 117997, Moscow

dr.surovtseva@yandex.ruhttps://orcid.org/0000-0003-3494-6614АндрияновД. В.AndriyanovDmitry V.

Андриянов Дмитрий Валериевич

117997, Москва, ул. Островитянова, д. 1

1 Ostrovityanova street, 117997, Moscow

Andriynov-Dima@yandex.ruРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова; НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФРоссияPirogov Russian National Research Medical University; Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of SciencesRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation202130072021183239244Copyright © Привалова Т.Е., Суровцева О.В., Андриянов Д.В., 20212021Привалова Т.Е., Суровцева О.В., Андриянов Д.В.Privalova T.E., Surovtseva O.V., Andriyanov D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2021

Папилломавирусная инфекция (ВПЧ-инфекция) по распространенности занимает лидирующее место среди инфекций, передающихся половым путем. ВПЧ-инфекция и ассоциированные с ней заболевания, в том числе онкологические, остаются одной из глобальных проблем современности. В литературном обзоре представлены актуальные данные зарубежных исследований и отечественных работ о состоянии вакцинации против ВПЧ в мире, об эффективности применения современных вакцин для профилактики ВПЧ-ассоциированных заболеваний, об используемых в настоящее время стратегиях вакцинации и их эффективности. Целью статьи является определение преимуществ гендерно-нейтральной стратегии вакцинации перед приоритетно используемой стратегией вакцинации только девочек при профилактике ВПЧ-ассоциированных заболеваний, в том числе онкологических, а также для искоренения инфекции ВПЧ в целом.

Papillomavirus infection (HPV infection) is the leading sexually transmitted infection in prevalence. HPV infection and associated diseases, including cancer, remain one of the global problems of our time. This literature review presents relevant data from foreign studies and domestic works on the state of HPV vaccination in the world, the modern vaccines efficacy for the HPV-associated diseases prevention, current vaccination strategies and their efficacy as well. The aim of the article is to determine the advantages of using gender-neutral vaccination strategy over priority-used vaccination strategy for girls only in the prevention of HPV-associated diseases, including cancer, as well as for eradicating HPV infection in general.

вирус папилломы человекаВПЧ-ассоциированные заболеваниявакцинациястратегии вакцинациигендерно-нейтральная вакцинацияhuman papillomavirusHPV-associated diseasesvaccinationvaccination strategiesgender-neutral vaccinationОтсутствуетNot specifiedReferencesHarden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12. doi: 10.1016/j.mrrev.2016.07.002Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12. doi: 10.1016/j.mrrev.2016.07.002Bacaj P, Burch D. Human Papillomavirus Infection of the Skin. Arch Pathol Lab Med. 2018;142(6):700-705. doi: 10.5858/arpa.2017-0572-RABacaj P, Burch D. Human Papillomavirus Infection of the Skin. Arch Pathol Lab Med. 2018;142(6):700-705. doi: 10.5858/arpa.2017-0572-RALuria L, Cardoza-Favarato G. Human Papillomavirus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 24, 2021. Available online: https://www.statpearls.com/ArticleLibrary/viewarticle/23034. Accessed on July 6, 2021.Luria L, Cardoza-Favarato G. Human Papillomavirus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 24, 2021. Available online: https://www.statpearls.com/ArticleLibrary/viewarticle/23034. Accessed on July 6, 2021.Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224-229. doi: 10.1002/ijc.31027Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224-229. doi: 10.1002/ijc.31027Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890. doi: 10.3390/v7072802Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890. doi: 10.3390/v7072802Bravo IG, Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015(1):32-51. doi: 10.1093/emph/eov003Bravo IG, Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015(1):32-51. doi: 10.1093/emph/eov003Nunes EM, Talpe-Nunes V, Sichero L. Epidemiology and biology of cutaneous human papillomavirus. Clinics (Sao Paulo). 2018;73(Suppl 1):e489s. doi: 10.6061/clinics/2018/e489sNunes EM, Talpe-Nunes V, Sichero L. Epidemiology and biology of cutaneous human papillomavirus. Clinics (Sao Paulo). 2018;73(Suppl 1):e489s. doi: 10.6061/clinics/2018/e489sEgawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119-127. doi: 10.1016/j.virusres.2016.12.017Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119-127. doi: 10.1016/j.virusres.2016.12.017Papillomavirus Episteme (PaVE): A resource of the Bioinformatics and Computational Biosciences Branch at the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology. Available online: https://pave.niaid.nih.gov. Accessed on March 30, 2021.Papillomavirus Episteme (PaVE): A resource of the Bioinformatics and Computational Biosciences Branch at the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology. Available online: https://pave.niaid.nih.gov. Accessed on March 30, 2021.Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28-37. doi: 10.1016/j.sxmr.2019.09.005Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28-37. doi: 10.1016/j.sxmr.2019.09.005Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7(9):241. doi: 10.3390/jcm7090241Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7(9):241. doi: 10.3390/jcm7090241Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920-1928. doi: 10.1080/21645515.2019.1600985Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920-1928. doi: 10.1080/21645515.2019.1600985Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016;8(8):75. doi: 10.3390/cancers8080075Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016;8(8):75. doi: 10.3390/cancers8080075Bratman SV, Bruce JP, O'Sullivan B, et al. Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):823-826. doi: 10.1001/jamaoncol.2015.6587Bratman SV, Bruce JP, O'Sullivan B, et al. Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):823-826. doi: 10.1001/jamaoncol.2015.6587Wittekindt C, Wagner S, Sharma SJ, et al. HPV — A different view on Head and Neck Cancer. Laryngorhinootologie. 2018;97(S 01):S48-S113. doi: 10.1055/s-0043-121596Wittekindt C, Wagner S, Sharma SJ, et al. HPV — A different view on Head and Neck Cancer. Laryngorhinootologie. 2018;97(S 01):S48-S113. doi: 10.1055/s-0043-121596Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016;30(3):245-249.Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016;30(3):245-249.Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219-2229. doi: 10.1002/cncr.30588Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219-2229. doi: 10.1002/cncr.30588Ilboudo M, Zohoncon TM, Traore IMA, et al. Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. Am J Otolaryngol. 2019;40(3):368-371. doi: 10.1016/j.amjoto.2019.02.003Ilboudo M, Zohoncon TM, Traore IMA, et al. Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. Am J Otolaryngol. 2019;40(3):368-371. doi: 10.1016/j.amjoto.2019.02.003National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER). Available online: https://seer.cancer.gov/sta-tistics. Accessed on March 30, 2021.National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER). Available online: https://seer.cancer.gov/statistics. Accessed on March 30, 2021.World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. Available online: https://gco.iarc.fr. Accessed on March 30, 2021.World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. Available online: https://gco.iarc.fr. Accessed on March 30, 2021.Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus-Associated Cancers — United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918-924. doi: 10.15585/mmwr.mm6733a2Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus-Associated Cancers — United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918-924. doi: 10.15585/mmwr.mm6733a2World Health Organization. Recomendations for routine immunization (updated: September 2020) Available online: http://www.who.int/immunization/policy/Immunization_routine_table1.pdf Accessed on February 20, 2021.World Health Organization. Recomendations for routine immunization (updated: September 2020) Available online: http://www.who.int/immunization/policy/Immunization_routine_table1.pdf Accessed on February 20, 2021.Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;2019:3257939. doi: 10.1155/2019/3257939Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;2019:3257939. doi: 10.1155/2019/3257939Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 Pt A):4768-4773. doi: 10.1016/j.vaccine.2017.12.079Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 Pt A):4768-4773. doi: 10.1016/j.vaccine.2017.12.079Stanley M, Dull P HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076Stanley M, Dull P HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(0 5):F123-F138. doi: 10.1016/j.vaccine.2012.04.108Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(0 5):F123-F138. doi: 10.1016/j.vaccine.2012.04.108Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759-768. doi: 10.1016/j.jaad.2015.05.041Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759-768. doi: 10.1016/j.jaad.2015.05.041Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723. doi: 10.1056/NEJMoa1405044Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723. doi: 10.1056/NEJMoa1405044Vesikari T, Brodszki N, van Damme P, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-998. doi: 10.1097/INF.0000000000000773Vesikari T, Brodszki N, van Damme P, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-998. doi: 10.1097/INF.0000000000000773Nyg rd M, Saah A, Munk C, et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015;22(8):943-948. doi: 10.1128/CVI.00133-15Nyg rd M, Saah A, Munk C, et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015;22(8):943-948. doi: 10.1128/CVI.00133-15Brotherton JML. Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res. 2019;7:138-140. doi: 10.1016/j.pvr.2019.04.004Brotherton JML. Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res. 2019;7:138-140. doi: 10.1016/j.pvr.2019.04.004Резолюция совета экспертов «Папилломавирусная инфекция: обзор накопленного опыта в решении мультидисциплинарной проблемы» // Эпидемиология и Вакцинопрофилактика. — 2018. — Т. 17. — № 6. — С. 109-113.Expert Council Resolution “Human Papillomavirus Infection: a Review of Experience in Solving a Multidisciplinary Problem”. Epidemiology and Vaccinal Prevention. 2018;17(6):109-113. (In Russ).Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597-1601. doi: 10.1111/jog.13419Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597-1601. doi: 10.1111/jog.13419World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage 2019 (data as July 2020). Available online: https://www.who.int/immunization/moni-toring_surveillance/who-immuniz.pdf. Accessed on February 20, 2021.World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage 2019 (data as July 2020). Available online: https://www.who.int/immunization/moni-toring_surveillance/who-immuniz.pdf. Accessed on February 20, 2021.Sheikh S, Biundo E, Courcier S, et al. A report on the status of vaccination in Europe [published correction appears in Vaccine. 2019 Feb 28;37(10):1374-1376]. Vaccine. 2018;36(33):4979-4992. doi: 10.1016/j.vaccine.2018.06.044Sheikh S, Biundo E, Courcier S, et al. A report on the status of vaccination in Europe [published correction appears in Vaccine. 2019 Feb 28;37(10):1374-1376]. Vaccine. 2018;36(33):4979-4992. doi: 10.1016/j.vaccine.2018.06.044Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectr. 2021;5(2):pkab011. doi: 10.1093/jncics/pkab011Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectr. 2021;5(2):pkab011. doi: 10.1093/jncics/pkab011Gavi. Overview of COVID-19 Situation in GAVI-Supported Countries and GAVI’s Response 30th June 2020. Available online: https://www.gavi.org/vaccineswork/30-june-2020-overview-covid-19-situation-gavi-supported-countries-gavi-response. Accessed on March 30, 2021.Gavi. Overview of COVID-19 Situation in GAVI-Supported Countries and GAVI’s Response 30th June 2020. Available online: https://www.gavi.org/vaccineswork/30-june-2020-overview-covid-19-situation-gavi-supported-countries-gavi-response. Accessed on March 30, 2021.Девятилова А.Н. Возможности профилактики и ранней диагностики рака шейки матки на региональном уровне // Смоленский медицинский альманах. — 2019. — № 1. — С. 95-97. [Devyatilova AN. Possibilities of prevention and early diagnosis of cervical cancer at the regional level. Smolensk medical almanac. 2019;(1):95-97. (In Russ).]Devyatilova AN. Possibilities of prevention and early diagnosis of cervical cancer at the regional level. Smolensk medical almanac. 2019;(1):95-97. (In Russ).Симаходский А.С., Ипполитова М.Ф. Опыт формирования и реализации региональной программы иммунизации детского населения Санкт-Петербурга против папилломавирусной инфекции // Эпидемиология и Вакцинопрофилактика. — 2019. — Т. 18. — № 3. — С. 65-70. [Simakhodsky AS, Ippolitova MF. Experience of Formation and Implementation of the Regional Program of Immunization of Children's Population of St. Petersburg against Papillomavirus Infection. Epidemiology and Vaccinal Prevention. 2019;18(3):65-70. (In Russ).] doi: 10.31631/2073-3046-2019-18-3-65-70Simakhodsky AS, Ippolitova MF. Experience of Formation and Implementation of the Regional Program of Immunization of Children's Population of St. Petersburg against Papillomavirus Infection. Epidemiology and Vaccinal Prevention. 2019;18(3):65-70. (In Russ). doi: 10.31631/2073-3046-2019-18-3-65-70Филиппов О.В., Большакова Л.Н., Елагина Т.Н., Новикова Ю.Б., Шаповалова РФ., Аристова А.М. Региональный календарь профилактических прививок в Москве: история, развитие, перспективы // Эпидемиология и Вакцинопрофилактика. — 2020. — Т. 19. — № 4. — С. 63-75. doi: 10.31631/2073-3046-2020-19-4-63-75Filippov OV, Bolshakova LN, Elagina TN, Novikova YuB., Shapovalova RF, Aristova AM. Regional Schedule of Vaccination in Moscow: History, Development, Prospects. Epidemiology and Vaccinal Prevention. 2020;19(4):63-75. (In Russ). doi: 10.31631/2073-3046-2020-19-4-63-75Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage among Adult Populations — United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi: 10.15585/mmwr.ss6611a1Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage among Adult Populations — United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi: 10.15585/mmwr.ss6611a1Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-5933. doi: 10.1016/j.vaccine.2018.06.074Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-5933. doi: 10.1016/j.vaccine.2018.06.074Public Health England. Human papillomavirus (HPV) vaccination coverage in adolescent females in England: 2018/19: Report for England. Avaliable online: https://assets.publishing.service. gov.uk/government/uploads/system/uploads/attachment_data/file/851797/HPV_annual_coverage_report_2018_to_2019.pdf. Accessed on March 30, 2021.Public Health England. Human papillomavirus (HPV) vaccination coverage in adolescent females in England: 2018/19: Report for England. Avaliable online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/851797/HPV_annual_coverage_report_2018_to_2019.pdf. Accessed on March 30, 2021.Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. doi: 10.15585/mmwr.mm6833a2Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. doi: 10.15585/mmwr.mm6833a2Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016. doi: 10.1136/bmj.h2016Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016. doi: 10.1136/bmj.h2016Vanska S, Luostarinen T, Baussano I, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020;222(6):948-956. doi: 10.1093/infdis/jiaa099Vanska S, Luostarinen T, Baussano I, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020;222(6):948-956. doi: 10.1093/infdis/jiaa099Faust H, Toft L, Sehr P, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-1565. doi: 10.1016/j.vaccine.2016.02.019Faust H, Toft L, Sehr P, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-1565. doi: 10.1016/j.vaccine.2016.02.019Lehtinen M, Luostarinen T, Vanska S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018;143(9):2299-2310. doi: 10.1002/ijc.31618Lehtinen M, Luostarinen T, Vanska S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018;143(9):2299-2310. doi: 10.1002/ijc.31618Drolet M, Benard Ё, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-580. doi: 10.1016/S1473-3099(14)71073-4Drolet M, Benard Ё, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-580. doi: 10.1016/S1473-3099(14)71073-4Cameron RL, Kavanagh K, Pan J, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56-64. doi: 10.3201/eid2201.150736Cameron RL, Kavanagh K, Pan J, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56-64. doi: 10.3201/eid2201.150736Brisson M, Benard Ё, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9Brisson M, Benard Ё, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catchup Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016;213(2):199-205. doi: 10.1093/infdis/jiv368Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catchup Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016;213(2):199-205. doi: 10.1093/infdis/jiv368Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study [published correction appears in Lancet Infect Dis. 2017 Jan;17 (1):17]. Lancet Infect Dis. 2017;17(1):68-77. doi: 10.1016/S1473-3099(16)30116-5Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study [published correction appears in Lancet Infect Dis. 2017 Jan;17 (1):17]. Lancet Infect Dis. 2017;17(1):68-77. doi: 10.1016/S1473-3099(16)30116-5Spinner C, Ding L, Bernstein DI, et al. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019;143(2):e20181902. doi: 10.1542/peds.2018-1902Spinner C, Ding L, Bernstein DI, et al. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019;143(2):e20181902. doi: 10.1542/peds.2018-1902Machalek DA, Chow EP Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202-208. doi: 10.1093/infdis/jiw530Machalek DA, Chow EP Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202-208. doi: 10.1093/infdis/jiw530Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208-212. doi: 10.1093/infdis/jix498Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208-212. doi: 10.1093/infdis/jix498Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949-958. doi: 10.1002/ijc.31119Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949-958. doi: 10.1002/ijc.31119

The authors declare that there are no conflicts of interest present.